These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37066201)

  • 1. Preclinical Screening of Splice-Switching Antisense Oligonucleotides in PDAC Organoids.
    Wan L; Kral AJ; Voss D; Krainer AR
    bioRxiv; 2023 Apr; ():. PubMed ID: 37066201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening Splice-Switching Antisense Oligonucleotides in Pancreas-Cancer Organoids.
    Wan L; Kral AJ; Voss D; Schäfer B; Sudheendran K; Danielsen M; Caruthers MH; Krainer AR
    Nucleic Acid Ther; 2024 May; ():. PubMed ID: 38716830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A patient-derived organoid-based study identified an ASO targeting SNORD14E for endometrial cancer through reducing aberrant FOXM1 Expression and β-catenin nuclear accumulation.
    Chen X; Liu X; Li QH; Lu BF; Xie BM; Ji YM; Zhao Y
    J Exp Clin Cancer Res; 2023 Sep; 42(1):230. PubMed ID: 37667311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hybridization-mediated off-target effects of splice-switching antisense oligonucleotides.
    Scharner J; Ma WK; Zhang Q; Lin KT; Rigo F; Bennett CF; Krainer AR
    Nucleic Acids Res; 2020 Jan; 48(2):802-816. PubMed ID: 31802121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repair of aberrant splicing in growth hormone receptor by antisense oligonucleotides targeting the splice sites of a pseudoexon.
    David A; Srirangalingam U; Metherell LA; Khoo B; Clark AJ
    J Clin Endocrinol Metab; 2010 Jul; 95(7):3542-6. PubMed ID: 20427506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of the regulatory effects of synthesized antisense oligonucleotides on androgen receptor (AR) exon 3 splicing in prostate cancer cells.
    Wang L; Gong S; Zhang X; Azhar Z; Chen J
    Gene; 2023 May; 866():147330. PubMed ID: 36871670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deep screening of proximal and distal splicing-regulatory elements in a native sequence context.
    Recinos Y; Ustianenko D; Yeh YT; Wang X; Jacko M; Yesantharao LV; Wu Q; Zhang C
    bioRxiv; 2023 Aug; ():. PubMed ID: 37662340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases.
    Chen S; Heendeniya SN; Le BT; Rahimizadeh K; Rabiee N; Zahra QUA; Veedu RN
    BioDrugs; 2024 Mar; 38(2):177-203. PubMed ID: 38252341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development.
    Dhuri K; Bechtold C; Quijano E; Pham H; Gupta A; Vikram A; Bahal R
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32604776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming imatinib resistance conferred by the
    Liu J; Bhadra M; Sinnakannu JR; Yue WL; Tan CW; Rigo F; Ong ST; Roca X
    Oncotarget; 2017 Sep; 8(44):77567-77585. PubMed ID: 29100409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebral Organoids and Antisense Oligonucleotide Therapeutics: Challenges and Opportunities.
    Lange J; Zhou H; McTague A
    Front Mol Neurosci; 2022; 15():941528. PubMed ID: 35836547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery of GalNAc-Conjugated Splice-Switching ASOs to Non-hepatic Cells through Ectopic Expression of Asialoglycoprotein Receptor.
    Scharner J; Qi S; Rigo F; Bennett CF; Krainer AR
    Mol Ther Nucleic Acids; 2019 Jun; 16():313-325. PubMed ID: 30965276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation and delivery of splice-correction antisense oligonucleotides by amino acid modified polyethylenimine.
    Zaghloul EM; Viola JR; Zuber G; Smith CI; Lundin KE
    Mol Pharm; 2010 Jun; 7(3):652-63. PubMed ID: 20128628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of a Quality-By-Design Approach to Optimise Lipid-Polymer Hybrid Nanoparticles Loaded with a Splice-Correction Antisense Oligonucleotide: Maximising Loading and Intracellular Delivery.
    Thanki K; Papai S; Lokras A; Rose F; Falkenberg E; Franzyk H; Foged C
    Pharm Res; 2019 Jan; 36(3):37. PubMed ID: 30623253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response.
    Frappart PO; Walter K; Gout J; Beutel AK; Morawe M; Arnold F; Breunig M; Barth TF; Marienfeld R; Schulte L; Ettrich T; Hackert T; Svinarenko M; Rösler R; Wiese S; Wiese H; Perkhofer L; Müller M; Lechel A; Sainz B; Hermann PC; Seufferlein T; Kleger A
    United European Gastroenterol J; 2020 Jun; 8(5):594-606. PubMed ID: 32213029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug.
    Alors-Perez E; Blázquez-Encinas R; Alcalá S; Viyuela-García C; Pedraza-Arevalo S; Herrero-Aguayo V; Jiménez-Vacas JM; Mafficini A; Sánchez-Frías ME; Cano MT; Abollo-Jiménez F; Marín-Sanz JA; Cabezas-Sainz P; Lawlor RT; Luchini C; Sánchez L; Sánchez-Hidalgo JM; Ventura S; Martin-Hijano L; Gahete MD; Scarpa A; Arjona-Sánchez Á; Ibáñez-Costa A; Sainz B; Luque RM; Castaño JP
    J Exp Clin Cancer Res; 2021 Dec; 40(1):382. PubMed ID: 34857016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual Fluorescence Splicing Reporter Minigene Identifies an Antisense Oligonucleotide to Skip Exon v8 of the
    Fukushima S; Farea M; Maeta K; Rani AQM; Fujioka K; Nishio H; Matsuo M
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33266296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant RNA Splicing in Cancer and Drug Resistance.
    Wang BD; Lee NH
    Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30463359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of organoid models for pancreatic ductal adenocarcinoma and screening of individualized therapy strategy.
    Gong M; Meng H; Tan D; Li P; Qin J; An Q; Shi C; An J
    Animal Model Exp Med; 2023 Oct; 6(5):409-418. PubMed ID: 37890865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
    Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
    J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.